CD19/CD20/BCMA CAR-T
Phase 1Cell therapy
CD19/CD20/BCMA CAR-T is one of 52 small molecule programs targeting Lymphoma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
R-CHOP
IIncyte Biosciences Japan GK
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD19/CD20/BCMA CAR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details